Medical device giant St. Jude Medical (NYSE:STJ) enrolled the 1st patient in the pivotal phase of its Amplatzer Cardiac Plug clinical trial, which will compare the company’s Amplatzer device to long-term treatment with blood-thinning medication.
Structural Heart
St. Jude Medical launches Ilumien Optis in Japan
St. Jude Medical (NYSE:STJ) said its launched the Ilumien Optis device in Japan, calling it the only medical device on the market to combine fractional flow reserve and optical coherence tomography technology to allow doctors to evaluate the state and severity of coronary lesions.
Transcatheter mitral valves are going to the dogs
The field of transcatheter mitral valve repair may move more quickly in pet populations than it does in human medicine, according to a presentation during this week’s American College of Cardiology conference in San Francisco.
Researchers are hard at work on a technology, called MitralSeal, they they hope to bring to market to treat mitral valve regurgitation in dogs.
TAVI: Sapien going strong at 3 years, but leak risk remains “overwhelmingly” higher
Updated March 19, 2013, at 11:30 a.m. to reflect that the quote in paragraph 6 came from an ACC press release, not an Edwards press release.
Early results “encouraging” for Edwards’ redesigned Sapien XT valve
The PREVAIL flail: A contrarian view
"The good thing about bad news – it sells."
Do hybrid cars interfere with cardiac implants? Apparently not, study finds
In the 1st study of its kind to examine the interaction between hybrid cars and implantable cardiac devices, researchers found that the electromagnetic waves generated by the green vehicles don’t pose a threat.
"Hybrid cards do not generated clinically relevant amounts of [electromagnetic interference]," according to a team of researchers from the Mayo Clinic of Arizona. "It is safe for patients with ICD to interact with hybrid cars."
Boston Scientific’s Watchman heart implant shows improved safety profile in preliminary results
Boston Scientific (NYSE:BSX) today unveiled new results from a clinical trial of its Watchman stroke prevention device, reporting that the cardiac implant met 2 of 3 co-primary endpoints for safety and effectiveness compared with drug therapy.
Report: Boston Scientific issues alert on its lead-free S-ICD defibrillator
Updated March 8, 2013, 2:30 p.m. with comments from Boston Scientific.
FDA considers patent extension for Edwards’ Sapien TAVI heart implant
Boston Scientific to present full safety results for Watchman heart implant
Boston Scientific (NYSE:BSX) officials changed their mind about an up-coming presentation of study results regarding the company’s Watchman stroke prevention implant, deciding to present the full safety results.